Patents by Inventor Liang Deng

Liang Deng has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ELEVATOR INSTALLATION ROLLER WITH RESTRAINING ELEMENT
    Publication number: 20170081151
    Abstract: In an elevator installation a belt-like support is guided over a roller. The roller includes at least one restraining element, which is arranged laterally of a roller contact surface. Lateral jumping-off of the belt-like support from the roller is thereby prevented. The restraining element additionally has a guide surface inclined toward the roller contact surface.
    Type: Application
    Filed: May 16, 2014
    Publication date: March 23, 2017
    Inventors: Lin Han, Liang Deng
  • OLIGOMER-OPIOID AGONIST CONJUGATES
    Publication number: 20160375009
    Abstract: The invention provides compounds that are chemically modified by covalent attachment of a water-soluble oligomer. A compound of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from those of the compound not attached to the water-soluble oligomer.
    Type: Application
    Filed: August 25, 2016
    Publication date: December 29, 2016
    Inventors: Jennifer Riggs-Sauthier, Bo-Liang Deng, Timothy A. Riley
  • Oligomer-opioid agonist conjugates
    Patent number: 9512135
    Abstract: The invention provides compounds that are chemically modified by covalent attachment of a water-soluble oligomer. A compound of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from those of the compound not attached to the water-soluble oligomer.
    Type: Grant
    Filed: December 4, 2015
    Date of Patent: December 6, 2016
    Assignee: Nektar Therapeutics
    Inventors: Jennifer Riggs-Sauthier, Bo-Liang Deng, Timothy A. Riley
  • Oligomer-opioid agonist conjugates
    Patent number: 9458166
    Abstract: The invention provides compounds that are chemically modified by covalent attachment of a water-soluble oligomer. A compound of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from those of the compound not attached to the water-soluble oligomer.
    Type: Grant
    Filed: December 4, 2015
    Date of Patent: October 4, 2016
    Assignee: Nektar Therapeutics
    Inventors: Jennifer Riggs-Sauthier, Bo-Liang Deng, Timothy A. Riley
  • Oligomer modified diaromatic substituted compounds
    Patent number: 9421204
    Abstract: The invention relates to (among other things) oligomer modified diaromatic substituted compounds. A compound of the invention, when administered by any of a number of administration routes, exhibits advantages over non-oligomer modified diaromatic substituted compounds.
    Type: Grant
    Filed: November 24, 2015
    Date of Patent: August 23, 2016
    Assignee: Nektar Therapeutics
    Inventors: Jennifer Riggs-Sauthier, Bo-Liang Deng
  • OLIGOMER-OPIOID AGONIST CONJUGATES
    Publication number: 20160214990
    Abstract: The invention provides compounds that are chemically modified by covalent attachment of a water-soluble oligomer. A compound of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from those of the compound not attached to the water-soluble oligomer.
    Type: Application
    Filed: December 4, 2015
    Publication date: July 28, 2016
    Inventors: Jennifer Riggs-Sauthier, Bo-Liang Deng, Timothy A. Riley
  • STING CRYSTALS AND MODULATORS
    Publication number: 20160210400
    Abstract: The present invention provides STING crystals. The present invention also provides STING modulators that interact with sites present in and/or defined by such crystals. The present invention also provides methods of making and using such crystals and modulators. Other aspects and/or features of the present invention will be apparent to those skilled in the art, reading the present specification.
    Type: Application
    Filed: July 31, 2014
    Publication date: July 21, 2016
    Inventors: Dinshaw J. Patel, Thomas Tuschl, Roger Jones, Gunther Hartmann, Winfried Barchet, Thomas Zillinger, Weiyi Wang, Pu Gao, Liang Deng, Manuel Ascano, JR.
  • OLIGOMER-CONTAINING SUBSTITUTED AROMATIC TRIAZINE COMPOUNDS
    Publication number: 20160194294
    Abstract: The invention relates to (among other things) methods for treatment comprising administering oligomer-containing substituted aromatic triazine compounds. A compound of the invention, when administered by any of a number of administration routes, exhibits one or more advantages over corresponding compounds lacking the oligomer.
    Type: Application
    Filed: January 15, 2016
    Publication date: July 7, 2016
    Inventors: Jennifer Riggs-Sauthier, Bo-Liang Deng
  • OLIGOMER MODIFIED DIAROMATIC SUBSTITUTED COMPOUNDS
    Publication number: 20160143904
    Abstract: The invention relates to (among other things) oligomer modified diaromatic substituted compounds. A compound of the invention, when administered by any of a number of administration routes, exhibits advantages over non-oligomer modified diaromatic substituted compounds.
    Type: Application
    Filed: November 24, 2015
    Publication date: May 26, 2016
    Inventors: Jennifer Riggs-Sauthier, Bo-Liang Deng
  • OLIGOMER-OPIOID AGONIST CONJUGATES
    Publication number: 20160130276
    Abstract: The invention provides compounds that are chemically modified by covalent attachment of a water-soluble oligomer. A compound of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from those of the compound not attached to the water-soluble oligomer.
    Type: Application
    Filed: December 4, 2015
    Publication date: May 12, 2016
    Inventors: Jennifer Riggs-Sauthier, Bo-Liang Deng, Timothy A. Riley
  • Oligomer-containing substituted aromatic triazine compounds
    Patent number: 9266845
    Abstract: The invention relates to (among other things) methods for treatment comprising administering oligomer-containing substituted aromatic triazine compounds. A compound of the invention, when administered by any of a number of administration routes, exhibits one or more advantages over corresponding compounds lacking the oligomer.
    Type: Grant
    Filed: October 30, 2014
    Date of Patent: February 23, 2016
    Assignee: Nektar Therapeutics
    Inventors: Jennifer Riggs-Sauthier, Bo-Liang Deng
  • Oligomer-opioid agonist conjugates
    Patent number: 9233168
    Abstract: The invention provides compounds that are chemically modified by covalent attachment of a water-soluble oligomer. A compound of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from those of the compound not attached to the water-soluble oligomer.
    Type: Grant
    Filed: December 23, 2014
    Date of Patent: January 12, 2016
    Assignee: Nektar Therapeutics
    Inventors: Jennifer Riggs-Sauthier, Bo-Liang Deng, Timothy A. Riley
  • Oligomer-bis-chromonyl compound conjugates
    Patent number: 9233169
    Abstract: The invention provides oligomer-bis-chromonyl compound conjugates. The conjugates of the invention, when administered by any of a number of administration routes, exhibits advantages over previously administered compounds.
    Type: Grant
    Filed: February 20, 2015
    Date of Patent: January 12, 2016
    Assignee: Nektar Therapeutics
    Inventors: Jennifer Riggs-Sauthier, Bo-Liang Deng
  • Oligomer-opioid agonist conjugates
    Patent number: 9233167
    Abstract: The invention provides compounds that are chemically modified by covalent attachment of a water-soluble oligomer. A compound of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from those of the compound not attached to the water-soluble oligomer.
    Type: Grant
    Filed: December 23, 2014
    Date of Patent: January 12, 2016
    Assignee: Nektar Therapeutics
    Inventors: Jennifer Riggs-Sauthier, Bo-Liang Deng, Timothy A. Riley
  • Oligomer modified diaromatic substituted compounds
    Patent number: 9226970
    Abstract: Disclosed are compounds comprising diaromatic substituted compound residues, namely the anti-viral (anti-HIV) drug delavirdine, covalently attached via a linkage to water-soluble, non-peptidic oligomers, specifically to poly(ethylene glycol) (PEG) oligomers. A compound of the invention, when administered by any of a number of administration routes, exhibits advantages over non-oligomer modified diaromatic substituted compounds.
    Type: Grant
    Filed: February 22, 2011
    Date of Patent: January 5, 2016
    Assignee: Nektar Therapeutics
    Inventors: Jennifer Riggs-Sauthier, Bo-Liang Deng
  • Method for performing chip level electromagnetic interference reduction, and associated apparatus
    Patent number: 9204581
    Abstract: A method for performing chip level electromagnetic interference (EMI) reduction is provided, where the method is applied to an electronic device. The method includes: providing at least one EMI suppression circuit within at least one chip of the electronic device; and utilizing the at least one EMI suppression circuit within the at least one chip to perform EMI reduction on at least one signal within the at least one chip. In particular, the at least one chip includes a first chip and a second chip; and the at least one EMI suppression circuit includes a first EMI suppression circuit positioned within the first chip, and further includes a second EMI suppression circuit positioned within the second chip. An associated apparatus is also provided.
    Type: Grant
    Filed: November 14, 2012
    Date of Patent: December 1, 2015
    Assignee: MEDIATEK INC.
    Inventors: Long-Kun Yu, Kuo-Liang Deng
  • OLIGOMER-CALCIUM CHANNEL BLOCKER CONJUGATES
    Publication number: 20150335628
    Abstract: The invention provides small molecule drugs that are chemically modified by covalent attachment of a water soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the characteristics of the small molecule drug not attached to the water soluble oligomer.
    Type: Application
    Filed: August 6, 2015
    Publication date: November 26, 2015
    Inventors: Zhongxu Ren, Bo-Liang Deng, Jennifer Riggs-Sauthier, Micah Harvey
  • Oligomer conjugates of heteropentacyclic nucleosides
    Patent number: 9149538
    Abstract: The invention provides small molecule drugs that are chemically modified by covalent attachment of a water-soluble oligomer.
    Type: Grant
    Filed: June 6, 2014
    Date of Patent: October 6, 2015
    Assignee: Nektar Therapeutics
    Inventors: Bo-Liang Deng, Timothy A. Riley, Jennifer Riggs-Sauthier
  • Oligomer-calcium channel blocker conjugates
    Patent number: 9132200
    Abstract: The invention provides small molecule drugs that are chemically modified by covalent attachment of a water soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the characteristics of the small molecule drug not attached to the water soluble oligomer.
    Type: Grant
    Filed: April 30, 2014
    Date of Patent: September 15, 2015
    Assignee: Nektar Therapeutics
    Inventors: Zhongxu Ren, Bo-Liang Deng, Jennifer Riggs-Sauthier, Micah Harvey
  • Oligomer-anticholinergic agent conjugates
    Patent number: 9126926
    Abstract: The invention provides small molecule drugs that are chemically modified by covalent attachment of a water-soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different as compared to the characteristics of the small molecule drug not attached to the water-soluble oligomer.
    Type: Grant
    Filed: February 1, 2013
    Date of Patent: September 8, 2015
    Assignee: Nektar Therapeutics
    Inventors: Jennifer Riggs-Sauthier, Bo-Liang Deng